PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic JournalOpen Access

Toxics

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

Toxics has 1 tracked paper indexed in Blossom (2023) from 4 authors, most often covering LSD, MDMA and Psilocybin, across Microdosing and Set & Setting.

Published Papers

Open Accessmeta

Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines

A PRISMA-guided systematic review of ergolamines, simple tryptamines and phenylethylamines (33 studies from 3,032 records) finds that classic psychedelics are active at very low doses, non‑addictive and generally only harmful at extremely high doses, with no established lethal dose for LSD or psilocybin. MDMA appears to carry the greatest apparent toxicity—likely confounded by recreational misuse—and the authors emphasise that risk is strongly modulated by set and setting.

Published
February 3, 2023
Journal
Toxics
Authors
Henríquez-Hernández, L. A., Rojas-Hernández, J., Quintana-Hernández, D. J., Borkel, L. F.

Quick Facts

Papers Indexed
1
h-Index
63
Open Access
Yes
Publisher
MDPI
Country
Switzerland
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.